|« Previous month||Next month »|
31-Jan-2014 - Shipments of chicken pox vaccines from a troubled Belgian facility should recommence in early Q2 2014, says GSK, though the root cause of the manufacturing issues are still unknown.
30-Jan-2014 - Clarus Therapeutics has submitted to the FDA a testosterone replacement it claims overcomes the toxicity problems that have plagued other oral drugs like methyltestosterone.
30-Jan-2014 - CordenPharma has received certification of Potent Compound Safety at a US plant and joins a growing list of drugmakers looking to assure HPAPI safety, according to SafeBridge Consultants.
30-Jan-2014 - Increasing demand for HPAPIs has driven Patheon to invest in its Milton Park, UK manufacturing facility, the company says.
30-Jan-2014 - Big pharma rivals are joining forces to pursue a new generation of sophisticated counterfeiters, according to Pfizer and Eli Lilly.
29-Jan-2014 - Northwest Biotherapeutics has agreed with CMO Cognate Bioservices to begin a large-scale expansion of the manufacturing, storage, handling and distribution of its personalized immune therapies for solid tumor cancers.
27-Jan-2014 - Daiichi-Sankyo says ensuring API supply could be a problem at Ranbaxy’s US finished product sites after imports are banned from yet another of its Indian facilities.
27-Jan-2014 - Actavis has announced plans to sell its stake in its Chinese subsidiary just days after telling investors the country is 'too risky' for new investments.
27-Jan-2014 - A French subsidiary of specialty ingredients firm Seppic has become the latest supplier certified under the Excipact quality scheme for drug excipients
27-Jan-2014 - The future of the organisation that makes many of Croatia’s drugs and immunotherapies is in doubt, with reports suggesting the Government is trying to sell off parts of the state...
27-Jan-2014 - Par Pharmaceutical Companies has agreed to buy JHP Group Holdings for $490M (€358M) to add sterile injectables to its offering.
23-Jan-2014 - Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.
23-Jan-2014 - The contentious drug Midazolam is no longer in short supply, the FDA has told In-PharmaTechnologist.com.
23-Jan-2014 - Rexam has completed its extension of a French plant that manufactures the nasal spray pump product, Advancia.
23-Jan-2014 - Higher earnings and improved margins did not impress investors in Lonza, which saw its share price tumble today after revealing that sales to the drug sector fell in 2013.
22-Jan-2014 - Eli Lilly is spending €75m ($102m) to meet latest global anti-counterfeiting regulations, its security experts said in an exclusive interview with in-Pharmatechnologist.com.
22-Jan-2014 - Novartis says it intends to shutter a New York manufacturing site due to reduced demand following the loss of exclusivity on its one-time topseller Diovan.
22-Jan-2014 - Teva Pharmaceutical Industries has agreed to acquire NuPathe for $144m (€106m) and gain access to the company’s transdermal patch.
21-Jan-2014 - European dependence on drugs and APIs made outside the EU is still ‘alarming’ despite recently introduced anti-falsified meds laws according to the European Fine Chemicals Group (EFCG).
21-Jan-2014 - Efforts to address the current shortage of IV fluids in the US are a placing a strain on manufacturing capabilities according to Baxter, which is investing to try and increase...
20-Jan-2014 - Aurobindo says it can make the loss making European generics operations it is buying from Actavis profitable by combining them with its production network in India.
20-Jan-2014 - AMRI says it intends to expand its fill/finish capability and progress its business into higher value technology following the recent all clear at its once troubled Burlington facility.
20-Jan-2014 - GSK Nigeria has a surprise MD resignation, Mylan tells us about its expansion in Latin America, and we cover the rest of the week's pharma hires.
20-Jan-2014 - The US FDA is positioned to increase drug plant inspections in China after US President Barack Obama signed a $1.1tr (€881bn) budget for fiscal 2014 into law on Saturday.
16-Jan-2014 - Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.
|« Previous month||Next month »|